Nimbus Therapeutics LLC

Plus: Jon Garay Alonso named CFO of Almirall, and updates from Certara and Immunai

Japanese pharma’s parent chooses $3.4B buyout to create PE-backed standalone company

Plus: Germany-based Topas taps new CEO, and updates from Quest, Nimbus and more

As the first two programs targeting the helicase WRN enter the clinic for MSI+ cancers, they set up a comparison of different inhibitory mechanisms

The clinical and commercial successes needed for Bristol Myers to navigate its upcoming patent cliff

Data reported in SITC abstracts show single-digit percentage responses

Plus: Moderna, Immatics in oncology discovery, development deal, and updates from Takeda, Novartis, Crinetics, Verona, Nestlé

With GV joining investor syndicate, the biotech’s ‘non-linear’ path will include HPK1 program rivaling Pfizer’s, as well as immunology and metabolic assets

Among dozens of companies that raised crossover cash before markets turned sour, some may soon have what it takes to go public

Nearly three years after firm’s separation, former parent still a presence, while new hires and sector headwinds drive investment decisions